Keyphrases
AIDS/HIV
64%
Zidovudine
55%
Infected children
48%
Human Immunodeficiency Virus Type 1 (HIV-1)
36%
AIDS Clinical Trials
32%
Tuberculosis
25%
Human Immunodeficiency Virus Infection
22%
Pediatric AIDS
20%
Directly Observed Therapy
17%
Infections in children
16%
Group Communication Protocol
13%
Exposed Infants
13%
HIV-exposed children
12%
Prevention Trials
12%
Perinatal Transmission
12%
Pharmacokinetics
11%
Viral
11%
United States
10%
Tuberculosis Disease
9%
Uninfected Infants
9%
Enzyme-linked Immunosorbent Assay (ELISA)
8%
Isoniazid Prophylaxis
8%
Pediatric Patients
7%
Therapy Adherence
7%
Pediatric
7%
HIV+
7%
Mycobacterium Avium Complex
7%
Tuberculosis Infection
7%
Transmission Risk
7%
Placebo
6%
Latent Tuberculosis Infection
6%
In Utero Exposure
6%
Highly Active Antiretroviral Therapy (HAART)
6%
African children
6%
Neonatal Exposure
6%
Rapid Progression
6%
Antiviral Drugs
6%
Antiretroviral
5%
Didanosine
5%
Long-term Survival
5%
HIV Surveillance
5%
Lymphocytic Choriomeningitis
5%
DRB1
5%
Extrapyramidal Syndrome
5%
Nucleosides
5%
Treatment of HIV Infection
5%
Meningitis
5%
Immunogenicity
5%
Medical Consultation
5%
High Prevalence
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Zidovudine
57%
Clinical Trial
35%
Human Immunodeficiency Virus 1
35%
Isoniazid
22%
Human Immunodeficiency Virus Infection
15%
Infection
14%
Pharmacokinetics
11%
Disease
11%
Tuberculosis
10%
Diseases
8%
Neoplasm
8%
Placebo
7%
Latent Tuberculosis
6%
Immune Deficiency
6%
Anemia
5%
Didanosine
5%
Nucleoside
5%
Human Alphaherpesvirus 1
5%
Pandemic
5%
Tolerability
5%
Drug Safety
5%
Hypochlorite Sodium
5%
Antiinfective Agent
5%
Clostridium septicum
5%
Gas Gangrene
5%
Symptom
5%
Toll Like Receptor 3
5%
Extrapyramidal Syndrome
5%
Encephalitis
5%
Lung Infection
5%
Secondary Infection
5%
Epileptic Absence
5%
Rifapentine
5%
Ritonavir
5%
Metabolic Acidosis
5%
Pharmacodynamics
5%
Gamma Interferon Receptor
5%
Human Immunodeficiency Virus 1 Infection
5%
Nevirapine
5%
Disorders of Mitochondrial Functions
5%
Medicine and Dentistry
Human Immunodeficiency Virus
61%
Pediatrics
25%
Zidovudine
23%
Infection
23%
Human Immunodeficiency Virus Infection
22%
Clinical Trial
18%
Human Immunodeficiency Virus 1
17%
Neoplasm
13%
Acquired Immune Deficiency Syndrome
13%
Disease
11%
Symptom
9%
Diseases
8%
Meningitis
7%
Lymphocyte
7%
Human Immunodeficiency Virus 1 Infection
7%
Immune Deficiency
6%
Neonatal Infant
6%
Lung Infection
6%
Pneumocystis Pneumonia
6%
Lymphocytic Choriomeningitis
5%
Blood Product
5%
Infancy
5%
Human Alphaherpesvirus 1
5%
Smooth Muscle
5%
COVID-19
5%
Cohort Effect
5%
Toll Like Receptor 3
5%
Kaposi Sarcoma
5%
Bronchiolitis
5%
Gas Gangrene
5%
Late Effect
5%
Clostridium septicum
5%
Encephalitis
5%
Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase
5%
Metabolic Acidosis
5%
Herpes Simplex Encephalitis
5%
Mycobacterium Chimaera
5%
Pediatrics Patient
5%
Chronic Granulomatous Disease
5%
Patient Compliance
5%
Monocyte
5%
Acidosis
5%
Congenital Tuberculosis
5%
In Vitro Fertilisation
5%
Heart Surgery
5%
Extrapyramidal Syndrome
5%
Interferon Alfa 2b
5%
Mycobacterium Avium-Intracellulare Infection
5%
Gamma Interferon Receptor
5%
